EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 4 (Avril 2009) Med Sci (Paris), 25 4 (2009) 341-343 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 4, Avril 2009
Page(s) 341 - 343
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2009254341
Published online 15 April 2009
  1. Spolski R, Leonard WJ. Interleukin-21 : basic biology and implications for cancer and autoimmunity. Ann Rev Immunol 2008; 26 : 57–79. [Google Scholar]
  2. Gougelet A, Mansuy A, Blay J. De l’eau au moulin de thérapies ciblant l’interleukine-6 dans les tumeurs épithéliales. Med Sci (Paris) 2008; 24 : 694–6. [Google Scholar]
  3. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008; 26 : 3445–55. [Google Scholar]
  4. Andorsky DJ, Timmerman JM. Interleukin-21 : biology and application to cancer therapy. Exp Opin Biol Ther 2008; 8 : 1295–307. [Google Scholar]
  5. Comes A, Rosso O, Orengo AM, et al. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 2006; 176 : 1750–8. [Google Scholar]
  6. Zeng R, Spolski R, Finkelstein SE, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005; 201 : 139–48. [Google Scholar]
  7. Wang G, Tschoi M, Spolski R, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003; 63 : 9016–22. [Google Scholar]
  8. Moroz A, Eppolito C, Li Q, et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity : Comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004; 173 : 900–9. [Google Scholar]
  9. Skak K, Kragh M, Hausman D, et al. Interleukin 21 : combination strategies for cancer therapy. Nat Rev Drug Discov 2008; 7 : 231–40. [Google Scholar]
  10. Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13 : 6419–28. [Google Scholar]
  11. Gowda A, Roda J, Hussain SRA, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibodydependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008; 111 : 4723–30. [Google Scholar]
  12. Akamatsu N, Yamada Y, Hasegawa H, et al. High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett 2007; 256 : 196–206. [Google Scholar]
  13. Sarosiek K, Chen J, Pham DG, et al. Interleukin-21-induced apoptosis and cell death of diffuse large-B cell lymphoma (DLBCL) cell lines and primary tumors are associated with an induction of Bim. ASH Annual Meeting. Blood 2006; 108 (suppl) : 2503 (abstract). [Google Scholar]
  14. Marzec M, Halasa K, Kasprzycka M, et al. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 2008; 68 : 1083–91. [Google Scholar]
  15. Yoon J, Newton S, Wysocka M, et al. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome. J Invest Dermatol 2008; 128 : 473–80. [Google Scholar]
  16. Iannello A, Tremblay C, Routy J, et al. Decreased levels of circulating IL-21 in HIV-infected AIDS patients : Correlation with CD4+ T cell counts. Viral Immunol 2008; 21 : 385–8. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.